Concourse Financial Group Securities, Inc. Bellus Health Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share
Q1 2023 May 15, 2023	BUY	$7.14 - $8.53 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$8.22 - $10.76 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$8.95 - $12.0 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$6.46 - $10.02 $0 - $0
Q1 2022 May 09, 2022	BUY	$5.56 - $7.99 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$5.26 - $8.3 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$2.7 - $6.64 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$3.11 - $4.61 $0 - $0
Q1 2021 May 13, 2021	BUY	$3.03 - $4.58 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$2.27 - $3.3 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$2.14 - $12.02 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$8.88 - $11.15 $0 - $0
Q1 2020 May 13, 2020	BUY	$5.77 - $10.85 $0 - $0
Q4 2019 Feb 14, 2020	BUY	$5.76 - $7.6 $0 - $0
Q3 2019 Nov 13, 2019	BUY	$6.24 - $8.84 $0 - $0

Others Institutions Holding BLU

# of Institutions

Shares Held

128K

Call Options Held

Put Options Held

Pendal Group LTD

128K
Shares

$0
0.01% of portfolio

View Full List

About BELLUS Health Inc.

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

More about BLU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account